Key results, originally scheduled to be presented at the American College of Cardiology's Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC),* demonstrated: 'For the first time, we are presenting real-world data that demonstrates that for these patients Andexxa was associated with the lowest in-hospital mortality across a variety of other treatment options.' Coleman, Pharm.D., University of Connecticut, School of Pharmacy and Hartford Hospital Evidence-Based Practice Center.

'The number of patients experiencing serious, life-threatening bleeding associated with Factor Xa inhibitors continues to increase as their use grows rapidly in the U.S. This included lower mortality across multiple bleed types including intracranial hemorrhage (ICH), gastrointestinal bleeding (GI) and bleeding due to trauma, when compared to 4-factor prothrombin complex concentrate (4F-PCC) therapy, which is approved only for the reversal of warfarin. The data demonstrated that Andexxa was associated with a lower rate of in-hospital and 30-day mortality in patients with life-threatening Factor Xa inhibitor-related bleeds compared with other treatment options.

® (Nasdaq: PTLA) today announced new data reinforcing the value of Andexxa ®, the first and only FDA-approved reversal agent for the Factor Xa inhibitors rivaroxaban or apixaban.

SOUTH SAN FRANCISCO, Calif., Ma/PRNewswire/ - Portola Pharmaceuticals, Inc.

Andexxa trial